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We identified a regulatory system that acts down-
stream of Wnt/b-catenin signaling in salivary gland
and head and neck carcinomas. We show in amouse
tumor model of K14-Cre-induced Wnt/b-catenin
gain-of-function and Bmpr1a loss-of-function muta-
tions that tumor-propagating cells exhibit increased
Mll1 activity and genome-wide increased H3K4 tri-
methylation at promoters. Null mutations of Mll1 in
tumor mice and in xenotransplanted human head
and neck tumors resulted in loss of self-renewal of
tumor-propagating cells and in block of tumor forma-
tion but did not alter normal tissue homeostasis.
CRISPR/Cas9 mutagenesis and pharmacological
interference of Mll1 at sequences that inhibit essen-
tial protein-protein interactions or the SET enzyme
active site also blocked the self-renewal of mouse
and human tumor-propagating cells. Our work
provides strong genetic evidence for a crucial role
of Mll1 in solid tumors. Moreover, inhibitors targeting
specific Mll1 interactions might offer additional
directions for therapies to treat these aggressive
tumors.
INTRODUCTION
Head and neck cancers comprise a heterogeneous group of tu-
mors that arise in the paranasal sinus, oral and nasal cavities,
pharynx and larynx, and salivary glands. 90% of these tumors
are squamous cell carcinomas and are newly diagnosed in
600,000 patients annually. Only 40%–50% will survive 5 years,
making this the fifth-most frequent malignant cancer worldwide
(Leemans et al., 2011; Morris et al., 2017). The most important
risk factors for head and neck squamous cell carcinomasCe
This is an open access article und(HNSCCs) are smoking, excess alcohol consumption, and
infection by high-risk human papillomaviruses (HPVs). Molecu-
lar therapies to treat advanced, recurrent, or metastatic
HNSCCs are lacking; radio- and chemotherapies and EGFR
antibody therapies using cetuximab have limited success and
are often accompanied by impairing side effects (Bauml
et al., 2016; Ja¨ckel and Scheckenbach, 2014; Matuschek
et al., 2016). Salivary gland squamous cell carcinomas (SG-
SCCs) are also difficult to treat, because they are aggressive
and produce early lymphatic metastases (Konings et al.,
2006; Ying et al., 2006).
Next-generation sequencing of HNSCCs has revealed
inactivating mutations of TP53, NOTCH1, NSD1, CDKN2A,
FBXW7, CASP8, and PTEN and activating mutations of
PIK3CA, HRAS, and others (Alioto et al., 2015; Cancer
Genome Atlas Network, 2015; Hoesli et al., 2017; Mountzios
et al., 2014). HNSCC tumors also exhibit activation of Wnt/
b-catenin signaling, and mutations have been found in the
Wnt pathway components AJUBA, FRZR, DKK3, and FAT1
(Cancer Genome Atlas Network, 2015; Dı´az Prado et al.,
2009; Katase et al., 2012). NOTCH, FAT1, and AJUBA, three
genes that can influence Wnt signaling via the inhibition of
b-catenin, are frequently altered in HPV carcinomas (Cancer
Genome Atlas Network, 2015; Haraguchi et al., 2008; Kwon
et al., 2011; Morris et al., 2013). A large consortium has re-
ported common molecular features of various human squa-
mous cell carcinomas from five sites, from head and neck to
bladder cancer, which correlated with DNA mutations and
methylations, microRNA expression, squamous cell stemness,
epithelial-to-mesenchymal differentiation, oxidative damage,
and other features. These findings support possibilities for
common therapeutic approaches for the different squamous
cell carcinomas (Campbell et al., 2018).
We showed in a previous report (Wend et al., 2013) that mice
harboring b-catenin gain-of-function (GOF) and Bmpr1a loss-of-
function (LOF) mutations driven by K14-Cre develop salivary
gland squamous cell carcinomas within 100 days after birth.ll Reports 26, 415–428, January 8, 2019 ª 2018 The Author(s). 415
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Aggressive tumors appeared rapidly in the salivary glands of the
double mutants. The tumors were classified as salivary gland
squamous cell carcinomas by histopathological criteria, con-
tained keratin pearls, and expressed high levels of the tumor
marker K10 (Chu and Weiss, 2002). These pieces of evidence
support the notion that Wnt/b-catenin signaling plays a signifi-
cant role in the progression of salivary gland tumors and in the
survival of mice.
Tumors contain tumor-propagating cells that have been linked
to therapy resistance and are increasingly considered prime tar-
gets for novel treatment strategies. Studies suggest that
Wnt/b-catenin signaling controls tumor-propagating cells in
HNSCCs. TheWnt antagonist sFRP4 reduced b-catenin expres-
sion and suppressed the stem cell markers CD44 and ALDH,
changes that were accompanied by reduced proliferation (War-
rier et al., 2014). Tumor-propagating cells also appear to play key
roles in the metastatic potential and the frequency of relapse of
HNSCCs (Prince et al., 2007; Zhang et al., 2012). We had shown
in our previous report (Wend et al., 2013) that more than 90% of
the mouse salivary gland CD24+DC29+SEEA1+ tumor-propa-
gating cells exhibited nuclear b-catenin and were low in Smad
1/5/8 compared to unsorted cells.
Histone methyltransferases such as mixed-lineage leukemia
(Mll) 1 help configure the chromatin environment as central
mechanisms of gene regulation, but it has not been clear how
the activity of Mll1 is regulated in solid cancer, and how it may
interact with Wnt/b-catenin signaling. Our previous study
showed that b-catenin, CBP, and Mll1 are critical for the tumor
growth and stem cell maintenance in vitro and with xenografts,
and they may be involved in a transcription complex that pro-
motes histone H3 lysine 4 (H3K4) tri-methylation in the tumor-
propagating population (Wend et al., 2013). Herewe investigated
the role of Mll1 in tumor initiation genetically, demonstrated that
the interaction between Mll1 and b-catenin is essential for their
functions, and defined the role of H3K4 methyltransferase activ-
ity in the transcriptional response to Wnt/b-catenin signals in
salivary gland squamous cell cancer in mice. We also demon-
strated similar mechanisms in human head and neck squamous
cell carcinoma cell lines.
RESULTS
Mouse Salivary Gland Tumor-Propagating Cells Display
an Epigenome Profile of H3K4 Hypermethylation
Mice harboring b-catenin gain-of-function (b-cateninf/+) and
Bmpr1a loss-of-function (Bmprf/f) mutations driven by Keratin
(K) 14-Cre develop salivary gland squamous cell carcinomas
within 100 days after birth (Figures S1A and S1B) (Wend et al.,
2013). The tumors were classified as SG-SCCs by histopatho-
logical criteria. Consistent with human tumors, mouse SG-
SCCs also showed high Wnt and low Bmp signals. In these
tumors, it is possible to distinguish a subpopulation endowed
with enhanced tumorigenic potential—referred to as tumor-
propagating cells—through the presence of nuclear b-catenin,
a hallmark of strongWnt signaling; another distinguishing feature
is the expression of K14 (Figure S1C, with tumor-propagating
cells marked by white arrowheads). By fluorescence-activated
cell sorting (FACS), tumor-propagating cells were enriched416 Cell Reports 26, 415–428, January 8, 2019from salivary gland tumors as CD24highCD29high cells and then
cultured as large spheres in non-adhesive conditions, which
rapidly propagated (Figures S1D and S1E). Spheres had
increased expression of stem cell-associated genes and Wnt/
b-catenin target genes, in contrast to adherent cells (Figure S1F).
Western blots of histone extracts showed enhanced modifica-
tion of H3K4 tri-methylation (H3K4me3) in sphere culture (Fig-
ure S1G). We had shown in our previous report (Wend et al.,
2013) that more than 90% of the mouse salivary gland
CD24+DC29+ cells exhibited nuclear b-catenin and a low level
of Smad 1/5/8 and were hyperproliferative and highly tumori-
genic when 500 cells were transplanted into the back skin of
non-obese diabetic-severe combined immunodeficiency
(NOD-SCID) mice, confirming them as tumor-propagating cells.
Unsorted cells were a little tumorigenic (100,000 cells were
required).
Cancer cells from salivary gland tumors were kept in
adherent (Ad) (differentiated cancer cell) or sphere (Sp) (tu-
mor-propagating cell) culture and then subjected to chromatin
immunoprecipitation sequencing (ChIP-seq) and mRNA
sequencing (mRNA-seq) using antibodies specific for histone
modifications: H3K4 monomethylation (H3K4me1), H3K4 di-
methylation (H3K4me2), and H3K4me3. An assessment of
normalized ChIP-seq read densities (in reads per million) in
peak regions showed marked enrichment of levels of
H3K4me1, H3K4me2, and H3K4me3 in sphere compared to
adherent cultures (Figures 1A–1C). The two states exhibited
significant differences in global peak enrichment and represen-
tation at transcriptional start sites (TSSs), as determined
through statistical comparisons (Figures S1H and S1I). The
main increases in H3K4me2 and H3K4me3, but not
H3K4me1, were observed in Sp cultures in regions of gene pro-
moters (Figure S1K, lower pictures, in blue), in which these
marks typically have an activating role for transcription. More-
over, upregulated genes showed globally increased levels of
H3K4me3 at promoter regions compared to downregulated
genes (Figure S1J) (difference 9.6e7). In Sp cultures, a high
level of H3K4me3 was observed at the promoter region of
Axin2, Id2, Tcf7l2, Tiam1, and Ephb3, well-characterized Wnt
target genes (Lustig et al., 2002) that are expressed at high
levels in Sp cultures, and was confirmed by RNA sequencing
(RNA-seq) (Figure 1D; Figures S2A–S2D). A similar pattern
was observed for Olfm4, an intestinal stem cell marker (van
der Flier et al., 2009), which is associated with Wnt activation
(Figure 1E). We also performed immunofluorescence analyses
of histone modifications on sections of salivary gland tumors:
H3K4me3 levels were enriched in nests of b-cateninhigh cells
(Figures 1F, upper panel, merged fluorescence on the right,
and 1G). In contrast, the polycomb-dependent repressive his-
tone mark histone H3 lysine 27 tri-methylation (H3K27me3)
was reduced in the nests of b-cateninhigh tumor-propagating
cells (Figures 1F, lower panel, and 1G). These results establish
that active Wnt/b-catenin signaling and chromatin modifica-
tions are linked through H3K4 tri-methylation. To identify which
groups of genes were mostly affected by H3K4me2 and
H3K4me3, gene ontology analysis was performed; it revealed
that genes involved in cytokine production pathway showed
elevated levels of H3K4me2 and H3K4me3 modification and
Figure 1. Histone Modifications in Salivary Gland Tumor Cells
(A–C) Comparison of global levels of H3K4me1 (A), H3K4me2 (B), and H3K4me3 (C) in tumor-propagating cells (sphere culture [Sp]) and differentiated cancer
cells (adherent culture [Ad]) using ChIP-seq. Fold changes of histone modifications on peak regions are plotted against the p value. Significantly changed peak
regions are marked in red. Values of three replicates were averaged.
(D and E) H3K4me changes in Ad and Sp cultures of Wnt/b-catenin target genes Axin2 (D) and Olfm4 (E). Promoter regions are marked horizontally.
(F) Immunofluorescence staining of cytokeratin 8 (blue), b-catenin (red), and histone H3 modifications (H3K4me3 and H3K27me3, green) on salivary gland tumor
sections. Merging of colors is shown on the far right.
(G) Quantification of viable H3K4me3 and H3K27me3 in tumor-propagating and tumor cells. Error bars, mean ± SD. ***p < 0.001.
See also Figures S1 and S2.mRNA expression in tumor-propagating cells (Figure S2H),
including Il1a, Il23a, and Cxcr2 (Figures S2E–S2G). In addition,
treatment with MI-2, which reduces the activity of Mll1 (Grem-
becka et al., 2012), downregulated the expression of these
genes (Figure S2I).
Mll1 Is Associated with Wnt/b-Catenin Signaling in
Salivary Gland Tumor-Propagating Cells
Mll methyltransferases produce methylated H3K4 in mammalian
cells (Wang et al., 2009). We analyzed the expression levels ofthe six Mll family members using quantitative real-time PCR in
freshly isolated salivary gland tumor cells and in cells following
adherent and sphere culture. Mutant b-cateninGOF; Bmpr1aLOF
tumor cells (called double-mutant tumor cells) showed mildly
reduced changes in the expression levels of theMll family mem-
bers compared to control and b-catenin single-mutant cells, and
the levels were similar to the ones observed in double-mutant tu-
mor cells propagated by adherent conditions (Figure S3A).
However, in sphere cultures of double-mutant tumor cells, in
which tumor-propagating cells are highly enriched (as describedCell Reports 26, 415–428, January 8, 2019 417
Figure 2. Homozygous Deletion of Mll1 Prevents Salivary Gland Tumor Formation
(A) Triple-mutant mice of the genotype K14-Cre; b-cateninf/+; Bmpr1af/f; Mll1f/fwere generated. The generation of the b-catenin andMll1 double-floxed allele was
confirmed by PCR genotyping (mouse 1171).
(B) Tumor-free survival curves are shown for mice with b-catenin; Bmpr1a double mutations (black curve, n = 35 mice), with b-catenin; Bmpr1a double mutations
and heterozygous Mll1 ablation (blue, n = 18 mice), and with b-catenin; Bmpr1a double mutations and homozygous Mll1 ablation (red, n = 20 mice).
(legend continued on next page)
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earlier), the expression levels of Mll1 and Mll3 were increased
(Figure S3A, far right).
Two members of the Mll family, Mll1 and Setd1a, have been
shown to interact in cell culture with the b-catenin transcription
factor complex involved in Wnt target gene activation (Salz
et al., 2014; Sierra et al., 2006). Because deletion of Mll3 had
no effect on tumor growth (as described later), and because
the expression of Setd1a was not upregulated in the spheres
(Figure S3A), we focused on Mll1. In cells, Mll1 binds indirectly
to b-catenin via the Creb-binding protein (CBP), a histone acetyl-
transferase (scheme in Figure S3B) (Arai et al., 2010; Ernst et al.,
2001; Takemaru and Moon, 2000). To test whether this interac-
tion also occurs in mouse salivary gland tumor-propagating
cells, b-catenin and the associated transcription factors LEF1
or TCF4 were immunoprecipitated from cells that were enriched
in sphere culture and analyzed by western blot. Both Mll1 and
CBP were detected in the immunoprecipitated b-catenin tran-
scription factor complex, whose predominant component was
TCF4 (Figure S3C). The formation of the complex was disrupted
after incubation with the Wnt inhibitor ICG-001, which blocks
b-catenin/CBP, and with LF3, which interferes with b-catenin/
TCF4 (Emami et al., 2004; Fang et al., 2016): immunoprecipita-
tion of Mll1 in the presence of ICG-001 showed reduced b-cate-
nin and TCF4 levels, but compound LF3 reduced only TCF4
(Figure S3D).
We also examined whether Wnt/b-catenin signaling regulates
the expression of Mll1 in salivary gland tumor cells. Sequences
upstream of the Mll1 gene were examined using the Patch1.0
program of Genexplain. This revealed five potential TCF-LEF
binding sites between positions 4 and 8 kb, which were
clustered in two regions, called regions 1 and 2 (Figure S3E).
To test whether these sites respond to Wnt activity, regions 1
and 2 were cloned into the luciferase reporter plasmid
pGL4.23 and transfected into HEK293 cells. Upon stimulation
of the Wnt pathway by the GSK3b inhibitor CHIR99021, which
is a strong Wnt activator, both regions responded to treatment.
However, region 2 was less sensitive to mild activation induced
by Wnt3a (Figure S3F). These results show that b-catenin phys-
ically interacts with the Mll1 protein complex in salivary gland
tumor cells and may contribute to the upregulated transcription
of the Mll1 gene.
Genetic Experiments Show that Mll1 Is Required for the
Initiation of Mouse Salivary Gland Tumors
To genetically examine the role of Mll1 in the generation of
mouse salivary gland tumors, we generated triple-mutant mice
with the genotype K14-Cre; b-cateninf/+; Bmpr1af/f; Mll1f/f (Fig-
ure 2A) (Kranz et al., 2010). The b-catenin and Mll1 genes in
mice are located on the same chromosome but at considerable
distance; therefore, we could generate mice with a version of
chromosome 9 that harbored both floxed b-catenin and floxed
Mll1 through chromosomal crossover during breeding, i.e.,
mouse 1171 (see PCR genotyping in Figure 2A). Thus, we finally(C) Histological comparison between salivary gland tissues of double-mutant m
arrowheads on the left show tumor lesions; black arrowheads on the right show
(D) Time-dependent rapid growth of filled tumor-like organoids with heterozygou
homozygous ablation of Mll1 (lower row of pictures).produced triple mutants, Mll1LOF/+ and Mll1LOF/LOF mice on the
tumor background (Figure 2B, upper part, crossings and
numbers of offspring). All triple-mutant mice carrying a heterozy-
gous deletion of Mll1 developed tumors by post-natal day (P)
100; the initiation and progression of the tumors were similar to
those of double-mutant mice (Figures 2B, lower part, compare
blue and black curves, and 2C, carcinomas in the left column,
marked by white arrowheads). In contrast, triple-mutant mice
with homozygous deletion of Mll1 did not produce tumors in
the salivary glands, even at 150 days (Figures 2B, red curve,
and 2C, right column). Only mild hyperplasia was observed at
late time points, P95 and P150 (Figure 2C, right column, marked
by black arrowheads).
We also examined the influence of Mll1 ablation on initiation
of salivary gland tumors in salivary gland organoid culture. Or-
ganoids were generated from b-cateninf/+; Bmpr1af/f; Mll1f/+
and b-cateninf/+; Bmpr1af/f; Mll1f/f cells, and mutations were
introduced by transduction with a retroviral construct produc-
ing Cre recombinase. Cells used to generate the organoids
also contained the floxed ROSA26EYFP/+ reporter allele, which
is activated by Cre. Cells with heterozygous ablation of Mll1
grew rapidly and formed tumor-like organoids that were filled,
unstructured, and highly proliferative (Figure 2D, upper panel;
Figure S4A, upper panel). In contrast, organoids with homozy-
gous ablation of Mll1 displayed reduced proliferation and an
increase in apoptosis (Figure 2D, lower panel; Figure S4A,
lower panel).
During development, homozygous Mll1 ablation driven
by K14-Cre (Mll1LOF) produced no changes in the overall
morphology and histological appearance of the salivary glands
(Figures S4B and S4C).Mll1LOFmice had similar numbers of sali-
vary gland ducts as control animals (Figure S4C, marked by
white arrowheads), and the distribution of cells marked by
EYFP was similar to that seen in control cells (Figure S4D,
marked by a broken white line).
Mll1 Is Required for Tumor Maintenance in Mouse
Salivary Gland Organoids
To examine whether Mll1 is also required for tumor mainte-
nance, we used the small molecule Mll1/Menin interaction in-
hibitor MI-2 that reduces the activity of Mll1 (Grembecka et al.,
2012). Control and b-cateninGOF; Bmpr1aLOF (double mutant)
cells were isolated from the salivary gland by FACS and
then raised in 3D culture to generate organoids (Clevers,
2016; Maimets et al., 2016). In 4 days, control organoids built
slow-growing lobular structures with basal and luminal cells,
which showed K14 and K8 expression, respectively (Figures
3A, upper panel, and 3B, upper panel), while double-mutant
cells generated fast-growing organoids that were filled and
were composed of basal K14-expressing cells as observed
in vivo (Figures 3A, lower panel, and 3B, second panel). The
Mll1 inhibitor MI-2 did not significantly affect the growth of
the control organoids (Figure 3B, third panel, quantified inice plus heterozygous and homozygous Mll1 ablation at different ages. White
hyperplastic lesions.
s ablation of Mll1 (upper row of pictures). Reduced growth of organoids with
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Figure 3. Mll1 Is Required for Tumor Main-
tenance inMouse Salivary GlandOrganoids:
Pharmacological Interference
(A) After organoid formation, K14, K8, and b-cat-
enin were stained by immunofluorescence:
b-catenin was located at the membranes in con-
trols (upper panel), while it was nuclear in orga-
noids from double-mutant tumors.
(B) After their formation, control organoids and
organoids from tumors were treated with the
pharmacological inhibitor MI-2 at 2 mM, and the
changes were monitored over time.
(C and D) Quantification of viable control (C)
and tumor (D) organoids after 4 days of treatment.
Error bars, mean ± SD. ***p < 0.001.
(E) Organoids from tumors were treated
with MI-2 at 2 mM. H3K4me3 was stained by
immunofluorescence.
(F) Quantification of viable fluorescence intensity
of treated and untreated organoids. ****p < 0.0001.
See also Figure S4.Figure 3C; Figure S4E, lower panel). In contrast, the growth of
double-mutant organoids was strongly inhibited by MI-2 (Fig-
ure 3B, fourth panel, quantified in Figure 3D), and apoptosis
was induced in the outer layer of the organoids (Figure S4F,
lower panel). Inhibition of enzymatic activity of Mll1 with
MI-2 reduced the level of H3K4me3 (Figures 3E and 3F). Alto-420 Cell Reports 26, 415–428, January 8, 2019gether, our genetic and pharmacolog-
ical experiments showed that Mll1 is
essential for the initiation and mainte-
nance of b-cateninGOF; Bmpr1aLOF
salivary gland tumors and tumor-like
organoids.
Conditional Mll1 Ablation Prevents
Survival of Tumor-Propagating
Cells in Salivary Gland Tumors
To assess mechanisms by which homo-
zygous Mll1 deletion prevents tumor
formation in the salivary glands, we exam-
inedWnt/b-cateninactivity, cell differentia-
tion, and apoptosis. In control salivary
glands, b-cateninwas located at themem-
branes in both K14- and K8-positive cells
(Figure S4G, marked by white arrow-
heads). Triple-mutant salivary glands with
heterozygous Mll1 deletion on the tumor
background exhibited nuclear b-catenin
staining inmanyK14-positive tumor-prop-
agating cells (Figures 4A, left column,
marked by white arrowheads, and 4B, up-
per left two pictures). In contrast, none of
the K14-positive cells in the epithelia of
homozygous Mll1 triple-mutant glands
showed nuclear staining of b-catenin (Fig-
ure 4A, right column, marked by cyan ar-
rowheads). The differentiation marker K8
and b-catenin were located at the mem-branes (Figure 4B, upper two right pictures, marked by white ar-
rowheads). Moreover, we observed increased apoptosis and
reducedproliferation in thehomozygousMll1 triple-mutant glands,
as shown by cleaved caspase-3 and Ki67 staining (Figure 4B,
compare third and fourth right pictures with the left ones). These
data show that Mll1 in the salivary gland tumors is required to
Figure 4. Mll1 Ablation in Salivary Gland Tumors Controls Differentiation and Apoptosis
(A) Immunofluorescence staining of K8, K14, and b-catenin in Mll1f/+ and Mll1f/f salivary gland mutant mice on the tumor background at different stages.
(B) EYFP, cleaved caspase-3, and Ki67 staining of Mll1f/+ and Mll1f/f mutant salivary glands on the tumor background.sustain highWntactivityand thatMll1ablationprevents thegrowth
of poorly differentiated cells and impairs their survival.
Mll1 Deletion Inhibits Proliferation of Mouse and Human
Head and Neck Cancer Cells
To further study the role of Mll1 in head and neck cancer cells
genetically, we carried out CRISPR/Cas9-based deletions in
theprimarymousesalivaryglandSG257cancer cells (FigureS1E)
and in the human head and neck cancer cell line HNSCCUM-03T
that exhibits highWnt activity (Figure 6D) and elevatedMll1 activ-
ity and H3K4me3 modification in the sphere culture condition
(Figures S6A and S6B) (Welkoborsky et al., 2003). Pairs of sin-
gle-guide RNAs (sgRNAs) were designed to remove the essential
exon 2 of mouse and human Mll1 (Figures S5B and S5G). Over
rounds of passaging, we observed the depletion of mouse and
human cells that harbored Mll1 mutant alleles, which were
induced by the sgRNA pairs sgMll1-3/5 for mouse cells and
sgMLL1-4/5 and sgMLL1-3/6 for human cells (Figures S5C,S5H, and S5I) (see the percentages of stepwise reductions).
Deletion of exon 2 ofMll2 andMll3 by CRISPR/Cas9 had no sig-
nificant influence on the growth of themouse tumor cells (Figures
S5J and S5K). To achieve a higher efficiency of deletion, we used
mouse cell clone SG257 6, in which one Mll1 allele had already
been deleted (Figures S5D and S5F), to perform second-round
deletions using the sgRNA pair sgMll1-4/6 (Figure S5B). During
passaging, cells with homozygous deletion ofMll1were outcom-
peted: the percentage ofMll1mutant alleles fell from94% to 50%
(Figure S5E). Five days after transfection of salivary gland SG257
cell clone 6 with sgMll1-4/6, we observed cell-cycle arrest at the
S phase (Figure S5L). These results indicate thatMll1 is required
for the growth of mouse and human tumor cells.
Mll1 Is Required for Tumor Initiation andMaintenance of
Human Head and Neck Cancer Cells
To further investigate the importance ofMll1 in human head and
neck cancer cells and tumors, we generated heterozygous andCell Reports 26, 415–428, January 8, 2019 421
Figure 5. Deletion of Mll1 Reduces Tumorigenesis of Human Head and Neck Cancer Cells
(A and B) PCR (A) and western blotting (B) showed Mll1 deletion in human HNSCCUM-03T cell clones 4 and 25.
(C and D) Influence of Mll1 deletion on proliferation (C) and self-renewal (D) of HNSCCUM-03T cells measured using 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphe-
nyltetrazolium Bromide (MTT) proliferation assays after 72 hr and sphere formation after 7 days. n = 3 independent experiments. Error bars, mean ± SD.
***p < 0.001 compared to parental cells.
(E and F) Apoptosis rate and cell-cycle distribution ofMll1/ HNSCCUM-03T cells analyzed using cleaved caspase-3 (E) and propidium iodide (F) DNA staining.
(legend continued on next page)
422 Cell Reports 26, 415–428, January 8, 2019
homozygous Mll1 knockout cell clones of HNSCCUM-03T cells
by deleting the essential exon 2 (Figure S6C).Mll1/ cell clones
were viable and showed strongly reduced production of Mll1
protein (Figures 5A and 5B; Figure S5A). The cell growth of ho-
mozygous mutant cells was slightly impaired, while their sphere
formation was strongly reduced (Figures 5C and 5D). Mll1/
cells exhibited increased apoptosis and cell-cycle arrest at the
S phase (Figures 5E and 5F). Gene expression profiling following
Mll1 ablation revealed silencing of Mll1 target genes like
HOXA11,HOXA9, and HOXA10 (Figure S6D). In gene set enrich-
ment analyses, Mll1/ cells exhibited upregulated apoptosis
and p53 signatures, along with downregulated cell-cycle genes
and E2F targets (Figure S6E). To examine their tumor-propa-
gating potential, Mll1+/ and Mll1/ cells were injected into
the back skin of NOD-SCID mice: Mll1+/ cells produced fast-
growing tumors upon injection of 500 or 5,000 cells, while
Mll1/ cells required higher numbers of cells to initiate tumori-
genesis, and these tumors grew more slowly (Figures 5G and
5H). In tumors formed by Mll1/ cells, we observed increased
apoptosis and reduced proliferation (Figure 5I; Figure S6F).
Overall, our data show that the deletion of Mll1 reduces pro-
liferation and increases apoptosis of mouse salivary gland
and human head and neck cancer cells and thus reduces
tumorigenesis.
Pharmacological Interference with the b-Catenin-Mll1
Complex Affects Tumor-Propagating Cells’ Self-
Renewal
To exert their functions as modulators of gene expression, both
Mll1 and b-catenin formmulti-protein complexes (scheme in Fig-
ure 6A). Menin is a direct N-terminal binding partner of Mll1 and
its fusion proteins and is required for the regulation of target
genes and leukemogenesis (Yokoyama et al., 2005). BRD4 is
an epigenetic reader of lysine acetylation that synergizes with
Mll1 fusion proteins at HOX loci to promote leukemogenesis
(Dawson et al., 2011; Muntean et al., 2010). Mll1 interacts indi-
rectly with b-catenin via CBP (Arai et al., 2010), and b-catenin
binds to DNA through TCF-LEF factors (Behrens et al., 1996; Fa-
solini et al., 2003). To assess the importance of these protein
partners on Mll1 function, we examined sphere formation in
the salivary gland SG257 cells (Figure S1E) in the presence of
the Mll1/Menin interaction inhibitor MI-2 (Grembecka et al.,
2012), the BRD4 inhibitor JQ1 (Grembecka et al., 2012), the
b-catenin/CBP interaction inhibitor ICG-001 (Emami et al.,
2004), the b-catenin/TCF4 interaction inhibitor LF3 (Fang et al.,
2016), and the CBP histone acetyltransferase enzyme activity in-
hibitor C646 and bromodomain inhibitor I-CBP112 (Bowers
et al., 2010; Picaud et al., 2015). In all cases except C646 and
I-CBP112, the inhibitors blocked the formation of spheres of
mouse salivary gland tumor cells in concentration-dependent
manners (Figure 6B). This shows that protein-protein interac-
tions of Mll1 to the partner molecules are crucial for the Mll1(G and H) Mll1+/ and Mll1/ HNSCCUM-03T cells (5,000, G, or 500, H) were tra
deletion on tumor initiation ability.
(I) (Left) Histological comparison between tumor xenografts initiated by parental,
shows the apoptosis rate of the different cells.
See also Figures S5 and S6.function but that the CBP enzyme activity is not crucial: CBP
seems to mediate the link between b-catenin and Mll1.
To test whether this holds true in humanHNSCCs, we included
further human HNSCC cell lines. The expression of AXIN2 and
HOXA9 was measured to indicate Wnt and Mll1 activity, respec-
tively. Among 9 cell lines, 4 of them have relatively high Wnt ac-
tivity and 3 of them have high HOXA9 expression (Figures S7A
and S7B), suggesting the Wnt and Mll1 activation is common
among human HNSCCs. Immunoprecipitation confirmed that
Mll1 and the b-catenin transcription factor complex interact in
HNSCCUM-03T sphere cells and that ICG-001 and LF3 inter-
fered in the expected manner (Figures S7C and S7D; compare
with mouse cells in Figures S3C and S3D). We tested the thera-
peutic potential of the inhibitors on HNSCCUM-03T high Wnt
cells, which possess a higher sphere-forming ability but have a
proliferating rate similar to that of HNSCCUM-02T cells that
show low Wnt activity (Figure 6C; Figure S7E) (Welkoborsky
et al., 2003). Sphere formation of HNSCCUM-03T cells was
strongly inhibited when treated with the interfering compounds
MI-2, JQ1, ICG-001, and LF3 (Figure 6C). Secondary sphere-for-
mation assays were performed to confirm the loss-of-self-
renewal phenotype (Figure S7F). In contrast, HNSCCUM-02T
and SCC4 cells, which exhibit low Wnt activity, were less sensi-
tive to the interfering compounds (Figures 6D and 6E). These re-
sults show that physical interactions between Mll1 and various
partners, including b-catenin, are critical to the support the
self-renewal capacity of Wnt-dependent human tumor-propa-
gating cells.
Protein-Protein Interaction Domains and the SET
Enzyme Activity of Mll1 Play Crucial Roles
Mll1 requires specific interactions with partner molecules
and the histone methyltransferase activity for H3K4 of the
su(var)3-9, enhancer-of-zeste and trithorax (SET) domain (Fig-
ure 6A). In particular, high SET activity requires the multiple pro-
tein partners of Mll1; of these, WDR5 is required specifically by
Mll1 (Li et al., 2016; Southall et al., 2009). To examine whether
these partner proteins and the methyltransferase activity of the
SET domain are required for maintaining tumor-propagating
cells, we used a modified procedure developed by Shi and col-
laborators (Shi et al., 2015) (Figure 7A). This involved first intro-
ducing a Cas9-mCherry expression cassette into the mouse
SG257 and human HNSCCUM-03T cells by a transposon sys-
tem. Then mCherry+ cells were enriched by FACS and
mixed with non-colored parental cells. Next, a lentiviral-based
construct was used to express different sgRNAs and a Puromy-
cin-resistance gene (Figure 7A). Specific sgRNAs targeted the
essential amino acids of Mll1: F9; L2838/I2842 in mouse and
L2848/I2852 in human cells; R3759 in mouse and R3768 in hu-
man cells, which conduct Mll1/Menin, Mll1/CBP, and Mll1/
WDR5 interactions; and the essential SET active site amino acids
Y3852/Y3936 in mouse and Y3861/Y3945 in human cells, alongnsplanted into the back skin of NOD-SCID mice to examine the effect of Mll1
Mll1+/, andMll1/ HNSCCUM-03T cells. (Right) Cleaved caspase-3 staining
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Figure 6. Targeting the b-Catenin/CBP/Mll1 Complex in Tumor-Propagating Cells by Small Molecule Inhibitors
(A) Scheme of the action of small molecule inhibitors targeting the b-catenin/CBP/Mll1 complex.
(B and C) Sphere-formation assays used to determine the influence of individual inhibitors on the self-renewal of mouse salivary gland SG257 cancer cells (B) and
human HNSCCUM-03T high Wnt head and cancer cells (C).
(D and E) Human HNSCCUM-02T and SCC4 low Wnt head and neck cancer cells with low self-renewal ability (D) and with no or less sensitivity to inhibitors (E).
n = 3 independent experiments. Error bars, mean ± SD. ***p < 0.001, *p < 0.05 compared to control.
See also Figure S7.with several neighboring non-essential sites (De Guzman et al.,
2006; Huang et al., 2012; Song and Kingston, 2008; Southall
et al., 2009). After Puromycin selection, mutant cells were sub-
jected to sphere culture for 10 days, and FACS was used to
analyze the ratios of mCherry+ cells.
We found that sgRNAs targeting regions of essential amino
acids of Mll1 effectively depleted mouse and human tumor-424 Cell Reports 26, 415–428, January 8, 2019propagating cells in sphere culture (Figures 7B and 7C, red
bars). In contrast, sgRNAs targeting regions neighboring these
essential sites caused only minimal negative-selection pheno-
types (black bars). Next-generation sequencing was used to
measure the abundance of the mutations after CRISPR/Cas9
editing: in-frame deletion mutations outcompeted frameshift
mutations when generated adjacent to the non-essential amino
Figure 7. CRISPR/Cas-Based Domain
Mutagenesis of Mll1
(A) Procedure of CRISPR/Cas-based domain
mutagenesis, sphere culture, and mCherry
analyses.
(B and C) Cas9-mCherry+ cells in mouse SG257
cells (B) and human HNSCCUM-03T cells (C)
after introduction of essential Mll1 mutations
(orange bars) and neighboring non-essential ones
(black bars) using various sgRNAs.
See also Figure S7.acids (Figure S7C, left). When generated adjacent to essential
amino acids, the ratio between the twomutation forms remained
the same (Figure S7C, right). Collectively, these findings show
that the SET enzyme activity and the Mll1/Menin, Mll1/CBP/
b-catenin and Mll1/WDR5 interactions are essential for the func-
tions of Mll1 in promoting the growth and survival of tumor-prop-
agating cells of the mouse salivary gland and human head and
neck tumor cells.
DISCUSSION
Global opening in the chromatin landscape has been shown in
embryonic and leukemia stem cells (Wong et al., 2015; Zoncu
et al., 2011). Relaxed chromatin structure, which is often
associated with transcriptional activation, is characterized by
enrichment of specific histone modifications such as H3K4 tri-
methylation. Our ChIP-seq andmRNA-seq data showed that sali-
vary gland tumor-propagating cells possess a globally elevated
level of H3K4me3 that is enriched at promoters and is associatedCellwith transcriptional activation. These re-
sults suggest that highly activated Wnt/
b-catenin signaling is linked to global
chromatin opening through H3K4 tri-
methylation in salivary gland and head
and neck cancers. Moreover, genes
involved in cytokine production pathways
showed elevated levels of H3K4me2 and
H3K4me3 modification, including Il1a,
Il23a, and Cxcr2, which, along with their
family members, are well-known cyto-
kines that participate in the remodeling of
the tumor microenvironment critical for
tumor initiation and progression (Holland
et al., 2013; Katoh et al., 2013; Langowski
et al., 2006; Wolf et al., 2001). This indi-
cates that in tumor-propagating cells,
Mll1 may have specific roles in the regula-
tion of the tumor microenvironment by
changing the cytokine production.
Mll1 mutations are reported in more
than 70% of acute leukemia in infants
and in 5%–10% of acute lymphoblastic
leukemia in adults (Winters and Bernt,
2017), indicating its essential roles in he-
matopoietic tumors. Mll1 is mutated in5.7% of human head and neck cancers (Cancer Genome Atlas
Network, 2015). Our data show that Mll1 is upregulated in
tumor-propagating cells of salivary gland and head and neck
cancers, and this is supported by high Wnt activity. Deletion of
Mll1 impairs the tumorigenesis significantly. This demonstrates
thatMll1 is also involved in the biology of solid tumors andmainly
regulated through transcriptional activation, which is supported
by other studies performed with cell cultures and xenografted
tumor cells (Ansari et al., 2013; Gallo et al., 2013; Heddleston
et al., 2012; Malik et al., 2015; Tamura et al., 2014; Zhu et al.,
2015). Here we provide genetic evidence that ablation of Mll1
blocks Wnt/b-catenin-driven tumorigenesis and show that Mll1
acts downstream of Wnt/b-catenin to control self-renewal, pro-
liferation, and apoptosis of salivary gland and head and neck
cancer. Moreover, we developed a unique organoid model sys-
tem to confirm Mll1 as a critical regulator for both initiation and
maintenance of salivary gland tumors.
In hematopoietic cancers, the N-terminal part of Mll1 un-
dergoes translocations to many partner molecules, suggestingReports 26, 415–428, January 8, 2019 425
that this region has crucial functions (Ayton and Cleary, 2001;
Dou and Hess, 2008; Meyer et al., 2013). Studies revealed that
leukemogenesis also requires thewild-typeMll1 allele, indicating
that the C-terminal domain is essential in leukemia (Thiel et al.,
2010). Our data obtained using CRISPR/Cas9-mediated muta-
genesis of both the essential interaction sites of Mll1 and the
SET enzyme active site strongly reduced self-renewal of human
and mouse tumor-propagating cells. These results demonstrate
that both N- and C-terminal regions of Mll1 are functionally
important in these solid cancers.
Given that small molecule inhibitors targeting Mll1 have been
pursued in the potential therapy for MLL-associated leukemia
(Cao et al., 2014), we envision that a similar strategy might cause
tumor impairment of human salivary gland and head and neck
cancer. Moreover, our data from menin inhibitor-2 (MI-2)-treated
control and tumor organoids demonstrated that malignant cells
were more sensitive than non-malignant cells to Mll1 inhibition,
indicating that targeting Mll1 might be a promising strategy to
inhibit these tumor cells. Whether combinations of Wnt and Mll1
inhibitors synergize in solid cancers is a question for subsequent
studies. Our salivary gland tumor organoids could also facilitate
the identification of further reagents with therapeutic potential.
Altogether, our study demonstrates that a further layer of
regulation acts downstream of Wnt/b-catenin in salivary gland
and head and neck cancer. This involves Mll1 action and
H3K4me3, which appear to trigger the opening of chromatin
that is required for promoting stem cell programs. In the future,
small molecule inhibitors that are able to target specific Mll1
functions could offer a promising direction for the development
of therapies to treat this important class of aggressive human
diseases.STAR+METHODS
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STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Rabbit polyclonal anti-H3K4me1 Diagenode Cat#C15410194; RRID:AB_2637078
Rabbit polyclonal anti-H3K4me2 Diagenode Cat#C15410035
Rabbit polyclonal anti-H3K4me3 Diagenode Cat#pAb-003-050; RRID:AB_2616052
Rabbit polyclonal anti- Histone H3 Abcam Cat#ab1791; RRID:AB_302613
Mouse monoclonal anti-b-catenin BD Bioscience Cat#610153; RRID:AB_397554
Rabbit monoclonal anti-Lef1 Cell Signaling Technology Cat#2230; RRID:AB_823558
Rabbit monoclonal anti-Tcf4 Cell Signaling Technology Cat#2569; RRID:AB_2199816
Rabbit polyclonal anti-Axin2 Cell Signaling Technology Cat#2151; RRID:AB_2062432
Mouse monoclonal anti-E-cadherin BD Bioscience Cat#610181; RRID:AB_397580
Rabbit polyclonal anti-Tri-Methyl-Histone H3(Lys4) Cell Signaling Technology Cat#9727; RRID:AB_561095
Rabbit polyclonal anti-Tri-methyl histone H3 (Lys27) Millipore Cat#07-449; RRID:AB_310624
Rabbit polyclonal anti-H3 Abcam Cat#ab1791; RRID:AB_302613
Rabbit polyclonal anti-Mll1 Bethyl Cat#A300-086A; RRID:AB_242510
Rabbit polyclonal anti-Mll1 Bethyl Cat#A300-374A; RRID:AB_345243
Rabbit polyclonal anti-CBP(A22) Santa Cruz Biotechnology Cat#sc-369; RRID:AB_631006
Mouse monoclonal anti-a-Tubulin Sigma Aldrich Cat#T9026; RRID:AB_477593
Guinea pig polyclonal anti-Cytokeratin 8 ARP American Research
Products
Cat#03-GP-K8; RRID:AB_1541063
Mouse monoclonal anti-Cytokeratin 14 Thermo Fisher Scientific Cat#MA5-11599; RRID:AB_10982092
Rabbit polyclonal anti-Cleaved caspase-3 Cell Signaling Technology Cat#9661; RRID:AB_2341188
Rabbit monoclonal anti-Ki67 Lab Vision Cat#RM-9106; RRID:AB_2335745
Chemicals, Peptides, and Recombinant Proteins
ICG-001 Selleckchem S2662
LF3 Chemdiv 5743-0262
MI-2 Selleckchem S7618
JQ1 Toris 4499
C646 Sigma SML002
I-CBP112 Sigma SML1134
FGFb Thermofisher PGH0021
EGF Life technologies PHG0313
Insulin Sigma-Aldrich 91077C
Dexamethasone Sigma-Aldrich Dexamethasone
Wnt3a R&D 1324-WN
Y-27632 Selleckchem S1049
Tryplex GIBCO 12563
Matrigel Corning 356231
Critical Commercial Assays
iDeal ChIP-seq kit for Histone Diagenode C01010051
iDeal Library Preparation Kit Diagenode C05010020
TruSeq stranded mRNA library preparation kit Illumina 20020594
TruSeq SBS Kit v3-HS Illumina FC-401-3001
GeneChip 30IVT express kit Applied Biosystems 902416
(Continued on next page)
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REAGENT or RESOURCE SOURCE IDENTIFIER
Deposited Data
RNA-seq data This paper GEO: E-MTAB-7509
Microarray data, see Table S6 This paper N/A
Chip-seq data This paper GEO: E-MTAB-7514
Experimental Models: Organisms/Strains
C57BL/6J mouse strain Jackson Labs 000664
Mouse B6: K14-Cre(Dneo) Wend et al., 2013 N/A
Mouse B6: b-cateninflox Wend et al., 2013 N/A
Mouse B6: Bmpr1aflox Wend et al., 2013 N/A
Mouse B6: Mll1flox Chen et al., 2017 N/A
Mouse B6: K14-Cre; Bmpr1aflox/+; Mll1flox/+ This study N/A
Mouse B6: b-cateninflox/flox; Bmpr1aflox/flox; Mll1flox/flox This study N/A
Mouse B6: K14-Cre; b-cateninflox/+ Bmpr1aflox/flox; Mll1flox/flox This study N/A
Oligonucleotides
sgRNAs used for gene deletion, see Table S1 This study N/A
sgRNAs used for Mll1 domain mutagenesis, see Table S2 This study N/A
Primers for RT-qPCR and ChIP-qPCR, see Table S5 This study N/A
PCR Primers Used to Amplify Mll1 Mutant Regions for
Next Generation Sequencing Analysis, see Table S7
This study N/A
Software and Algorithms
Flowjo FLOWJO LLC N/A
R R-studio N/A
STAR Dobin et al., 2013 N/A
DESeq2 Hashimshony et al., 2016 RRID:SCR_015687; https://genomebiology.
biomedcentral.com/articles/10.1186/s13059-
014-0550-8
CRISPResso Pinello et al., 2016 http://crispresso.rocks/CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Walter
Birchmeier (wbirch@mdc-berlin.de).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell culture
In sphere culture, 24-well cell culture plates were pre-coated with 250 mL poly-hydroxyethyl-methacrylate (PolyHEMA, 12 mg/ml in
95% ethanol, Sigma). Cells were seeded as single cells in sphere culture medium (F12:DMEM 1:1, containing 1X B-27 supplement,
20 ng/ml EGF, 20 ng/ml FGF, 5 mg/ml insulin and 0.5% methylcellulose). For obtaining adherent cells, mouse salivary gland tumor
cells were cultured in DMEM/F12medium supplementedwith 20%knockout serum replacement (KSR), non-essential minimal amino
acids, penicillin/streptomycin solution, L-glutamine and b-mercaptoethanol (Invitrogen). Human head and neck carcinoma cell lines
were cultured in DMEM/F12 medium supplemented with 10% fetal bovine serum, penicillin and streptomycin. For self-renewal
assay, cells were treated and let to form spheres. Primary spheres were dissociated and plated in plates at 4 cell per microliter di-
lutions. MI-2 (3.125 mM) and DMSO treatments were performed for 7 days. After treatment, spheres were dissociated, counted, and
plated for self-renewal assay with the drugs. After 1 week, spheres were counted.
Mice
K14-Cre(Dneo), b-cateninflox, Bmpr1aflox, and Mll1flox mice and the Cre-inducible R26EYFP reporter allele have been described
(Harada et al., 1999; Huelsken et al., 2001; Kranz et al., 2010; Mishina et al., 2002; Srinivas et al., 2001). All mice used in this study
had a C57BL/6 background. The conditional gain-of-function mutation of b-catenin was produced by crossing homozygous mice
carrying the b-cateninlox(ex3) allele to K14-cre mice. The loss-of-function mutation of the Bmpr1a was produced by crossinge2 Cell Reports 26, 415–428.e1–e5, January 8, 2019
homozygous mice carrying Bmpr1aflox alleles to K14-cre mice that were homozygous for the Bmpr1aflox allele (Wend’s paper).
To obtainMll1 single mutant mice, male mice carrying K14-Cre; Mll1f/+were crossed with female mice carryingMll1f/+; R26EYFP/EYFP.
Due to the infertility of K14-Cre; b-cateninflox/+ mice, in order to obtain triple mutant mice, we first generated K14-Cre; Bmpr1aflox/+;
Mll1flox/+ mice and b-cateninflox/flox; Bmpr1aflox/flox; Mll1flox/flox mice. Both these two mouse strains were fertile and showed no aber-
rant phenotype. To generate K14-Cre; b-cateninflox/+ Bmpr1aflox/flox; Mll1flox/flox ; ROSA26EYFP/+, we always crossed male K14-Cre;
Bmpr1aflox/+; Mll1flox/+with female b-cateninflox/flox; Bmpr1aflox/flox; Mll1flox/flox ; ROSA26EYFP/+. Mutant mice were genotyped by PCR.
Animal experiments were performed according to the EU and national institutional regulations.
METHOD DETAILS
ChIP-Seq and mRNA-seq
Anti-H3K4me1 (C15410194), -me2 (C15410035) and -me3 (C15410003-50) antibodies were purchased from Diagenode. ChIP-seq
was performed according to the protocols provided by Diagenode using the iDeal ChIP-seq kit for histones and the iDeal library
preparation kit. For mRNA-seq, mRNA was extracted according to the standard TRIzol protocol (Invitrogen) and subjected to library
preparation using the TruSeq stranded mRNA library preparation kit. Sequencing was performed with the TruSeq SBS Kit v3-HS
(2 X 200 cycles) on an Illumina HiSeq 2000 sequencer.
Compounds
ICG-001 (25 mM; S2662, Selleckchem), LF3 (50 mM; 5743-0262, Chemdiv), MI-2 (50 mM; S7618, Selleckchem), JQ1 (25 mM; 4499,
Toris), C646 (25 mM; SML0002, Sigma) and I-CBP112 (25 mM; SML1134, Sigma) were prepared as concentrated stock solutions
in DMSO, and were diluted in culture medium to obtain the final concentrations. The final concentrations of DMSO were kept equal
for all treatments.
CRISPR/Cas-based Gene Deletion and Domain Mutagenesis
pSpCas9(BB)-2A-GFP (PX458) was a generous gift from Feng Zhang (Addgene plasmid # 48138). The PX458-mCherry plasmid was
generated by replacing theGFP cassette in PX458withmCherry. sgRNAswere designed on https://zlab.bio/guide-design-resources
and inserted into PX458-mCherry according to the protocol described (Ran et al., 2013). Target cells were transfected with con-
structed PX458-mCherry plasmids using Lipofectamine 2000. 48 h after transfection, mCherry+ cells were FAC-sorted for analyzing
gene deletion deficiency or generating mutant cell clones. sgRNAs used forMll1 deletion are listed in Table S1. The pT2-HB-Cas9-
2A-mCherry plasmidwas generated by inserting theCas9-2A-mCherry expression cassette into pT2-HB plasmid. pT2-HB-Cas9-2A-
mCherry and pCMV(CAT)T7-SB100 were co-transfected into target cells. After one week, stable mCherry-expressing cells were
FAC-sorted and mixed with parental cells at 4:1 ratios. sgRNAs targeting different domains of Mll1 were designed on https://zlab.
bio/guide-design-resources and inserted into the lentiGuide-Puro vector. Viral particles expressing sgRNAs were produced and
used to transduce target cells according to the described protocol (Sanjana et al., 2014). After Puromycin selection, cells were sub-
jected to sphere culture, and FACS was used to analyze the mCherry+ cells. sgRNAs used for Mll1 domain mutagenesis are listed in
Table S2.
Immunofluorescence and other Stainings
Immunofluorescence and H&E staining were performed on formalin-fixed paraffin-embedded tissue sections as we had described
(Huelsken et al., 2001). Antigen retrieval was accomplished by Tris-EDTA (10 mM Tris, 1 mM EDTA, 0.05% Tween-20, pH 9.0) at
99-100C for 20 minutes. Following retrieval, sections were stained by Hematoxylin-Eosin (HE) or different antibodies. The following
primary antibodies were used for immune-detection: mouse anti-b-catenin (from BD Transduction Laboratories), rabbit anti-tri-
methyl histone H3K4me3 and rabbit anti-tri-methyl histone H3K27me3 (Cell signaling), guinea pig anti-CK8, mouse anti-CK10
and rabbit anti-CK14 antibodies (Covance). Images were captured using an Axio imager.Z1m and AxioCam MRm (Carl Zeiss).
Quantitative Real-Time PCR
After desired treatments, cells were lysed in suitable amounts of TRIzol (Invitrogen), and 2 mg total RNAwas reverse-transcribed using
MMLV reverse transcriptase (Promega) according to the instructions by the manufacturers. qRT-PCR was performed using the
iCycler IQTM 5 multicolor real-time detection system (Bio-Rad) with absolute SYBR green fluorescein (ABgene). PCR was carried
out following a standard protocol: primer sequences used for qRT-PCR can be found in Table S5.
Immunoprecipitation and Western Blotting
For immunoprecipitation, cells were lysed in Co-IP buffer containing 50 mM Tris pH7.5, 150 mM NaCl, 1% NP-40, 10% Glycerol,
1 mM DTT, 1 mM PMSF, and protease inhibitor cocktail (Roche). 500 mg of total protein extract for each sample was pre-cleaned
by protein G Dynabeads (Thermo Fisher) at 4C for 1 h. Pre-cleaned lysate was sequentially incubated with anti-b-catenin
(610154, BD Transduction Laboratories), anti-Lef1 (2230, Cell signaling) and anti-Tcf4 antibodies (2953, Cell signaling) at 4C over-
night and subsequently with protein G Dynabeads for an additional 1 h. All washing and incubation steps were carried out in Co-IP
buffer. The bound proteins were eluted by boiling in SDS sample buffer and analyzed by western blotting.Cell Reports 26, 415–428.e1–e5, January 8, 2019 e3
Protein samples from different experiments were loaded onto 8%–12% SDS-PAGE, separated in the electrophoresis running
buffer (25 mM Tris, 20mM glycine, 2% SDS), and transferred onto PVDF membranes in the transfer buffer (25 mM Tris, 192 mM
glycine, 3% SDS, 10% methanol). Non-specific binding sites on the membranes were blocked for 1 h at room temperature (RT) in
blocking solution (4% BSA, 0.1% Tween20 in PBS) with constant shaking. The primary antibodies were diluted in blocking solution
and incubated with themembranes at 4Covernight with constant shaking. After washing in PBST (0.1%Tween20 in PBS), themem-
branes were incubated with the HRP-conjugated secondary antibodies diluted in blocking solution for 1 h. After washing three-times
in PBST, the immuno-reactive bands were visualized with Western lightning chemi-luminescence reagent plus (PerkinElmer) and a
Vilber Lourmat imaging system SL-3. The following primary antibodies were used for immune-detection: mouse anti-b-catenin
(from BD Transduction Laboratories), rabbit anti-b-catenin (Huelsken et al., 2001), rabbit anti-Axin2 and rabbit anti-tri-methyl histone
H3 (Lys4) (Cell Signaling), rabbit anti-tri-methyl histoneH3 (Lys27) (Millipore), rabbit anti-Mll1 (Bethyl), mouse anti-TCF4 antibody (Cell
Signaling), mouse anti-E-cadherin (BD Transduction Laboratories), rabbit anti-CBP and mouse anti-a-tubulin antibodies (Sigma).
Organoid Culture
Mouse salivary organoid cultures were generated and maintained as described in a protocol that we adapted (Maimets et al., 2016).
Briefly, murine salivary glands of mice with different genotypes were dissected and enzymatically digested with collagenase type II
(GIBCO) and Dispase. Cell aggregates were embedded directly in growth factor-reduced Matrigel (Corning). Cells with K14-Cre
activity bearing the EYFP-reporter were FACS-enriched before seeding. Matrigel was overlaid in a 1:10 ratio with Salivary gland
medium (SGM) composed of DMEM/F12 medium supplemented with B27 and N2, 10 mM HEPES, Glutamax, Penicillin/
Streptomycin (all from Life technologies), 1.25 mM N-acetylcysteine (N-AC, Sigma-Aldrich), and the following growth factors:
50 ng/ml EGF (Life technologies), 20 ng/ml FGFb (GIBCO), 10mg/ml insulin (Sigma-Aldrich) and 1mMdexamethasone (Sigma-Aldrich).
After FACS-enrichment, cells were cultured for 1 day in the presence of the 10mM Rock inhibitor Y-27632 (Selleck Chemical).
Organoids were passaged by cell dissociation using TrypLEX (GIBCO). For retrovirus infection, salivary gland organoids were disso-
ciated by TrypLEX (GIBCO) and transferred to SGM enriched with 500ng/ml Wnt3a (R&D), 5mM Nicotinamide (Sigma), 10mM Rock
inhibitor Y-27632, 8mg/ml Polybrene and the Cre-expressing virus (produced in Pho¨nix cells). After Spin occulation, cells were
cultured for 6h under non-adherent conditions in a cell culture incubator, before embedding into Matrigel and further cultured in
SGM. For compound treatment, salivary gland organoids were cultured in SGM supplemented with the indicated concentrations
of MI-2, with medium changes every second day for up to 4 days.
Cell Cycle and Apoptosis Analyses
Fresh cells were incubated with 5 mg/ml propidium iodide (Sigma) in PBS for 10 min and analyzed for cell death using FACS
(BD Transduction Laboratories). For apoptosis analyses, cells fixed with 3% formaldehyde were sequentially incubated with
anti-cleaved-caspase3 antibody (9661, Cell signaling) and DyLight488-conjugated secondary antibody (711-485-152, Jackson
ImmunoResearch laboratories) in PBS with 0.5% BSA. The percentage of cleaved-caspase3-positive cells was analyzed by the
FACS (BD Transduction Laboratories).
Xenotransplantation Studies
Cells with different genotypes (5000 or 500 cells) were subcutaneously injected into the back skin of NOD-SCID mice, 3 per group.
Tumor growth was monitored over a period of 100 days.
Gene Expression Profiling by Microarray
Total RNA of HNSCCUM-03T cells was extracted according to the standard TRIzol protocol (Invitrogen), and prepared with
GeneChip 30IVT express kit (Illumina) for the microarray analysis using Microarray U133A 2.0. Microarray data were processed
and analyzed with R Studio to find differentially regulated genes. Most differentially-regulated genes were subjected to gene set
enrichment analysis. Different gene sets were downloaded from http://software.broadinstitute.org/gsea/index.jsp. Microarray
gene expression data can be found in Table S6.
ChIP-seq and mRNA-seq Data Analysis
All sequencing reads weremapped using STAR (v 2.5.3a) with the parameter ‘‘-alignIntronMax 1’’ with the purpose of disable splicing
alignments. Peak detection was performed by MACS2 (default parameter for narrow peak detection) on bam files on each sample.
We created a unique reference peak file for each histone modification by merging all individual peak files. FeatureCounts software
was used for counting reads on each sample for the corresponding reference peak file. Significant (adjusted p value < 0.01) differ-
ential peak enrichments were identified by DESeq2. Peaks with low read counts (baseMean < 50) and small difference of enrichment
(log2FC < 0.6 or log2FC > 0.6) were discarded. The generation of Wig files for plotting the genome tracks was done by the Bio-
conductor packageMEDIPS. A slidingwindow of 50bpwas used to plot high resolution normalized fpkm values in thewhole genome.
ChIP-seq peak-calling data and mRNA-seq differential-expression data can be found in Tables S3 and S4.e4 Cell Reports 26, 415–428.e1–e5, January 8, 2019
Mutation Abundance Measurement by NGS
To analyze the mutation abundance of target regions, primary PCR was used to amplify mutant regions, and secondary PCR
was performed to add adaptors for next generation sequencing. PCR primers for these procedures are listed in Table S7. The
quantification of CRISPR genome editing outcomes were obtained using command line version of CRISPResso tool
(http://crispresso.rocks/). Indels were then assigned as Frameshift deletions (FS) and In-frame deletions (IF). FS were assigned,
when the number of deleted was not a multiple of three and IF, when the number of deleted was a multiple of three. Finally, reads
of 50 most abundant mutations (FS and IF) were added up, and the proportion of FS and IF was compared among the different
time points.
QUANTIFICATION AND STATISTICAL ANALYSIS
All data shown are presented as mean ± SEM, all the statistical details of experiments can be found in the figure legends. When
comparing datasets, two-tailed unpaired Student’s t test was applied using GraphPad Prism software, unless indicated. No statis-
tical methodwas used to estimate the sample size. No specific randomization or blinding protocol was used. N indicates the numbers
of independent biological replicas per experiment unless otherwise indicated. p % 0.05 was considered statistically significant.
Significance tests were performed on all samples and therefore graphs lacking p values indicate results were not statistically
significant.
DATA AND SOFTWARE AVAILABILITY
The accession numbers for the ChIP-seq and RNA-seq data reported in this paper can be found under Gene Expression Omnibus
GEO: E-MTAB-7514 and E-MTAB-7509, respectively.Cell Reports 26, 415–428.e1–e5, January 8, 2019 e5
